Pharmacological Prophylaxis of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis
Sponsor: Grigore T. Popa University of Medicine and Pharmacy
Listed as NCT03708458, this PHASE4 trial focuses on Post-ERCP Pancreatitis and remains ongoing. Sponsored by Grigore T. Popa University of Medicine and Pharmacy, it has been updated 5 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Nov 2018 — Nov 2020 [monthly]
Recruiting PHASE4
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grigore T. Popa University of Medicine and Pharmacy
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Iași, Romania